Holoxan2 gm/vial

Holoxan is an alkylating agent (oxazaphosphorine) chemotherapy medicine used in the treatment of certain cancers, always under the supervision of a physician experienced in cancer chemotherapy.

Established / Approved Use

• Germ cell testicular cancer: Holoxan is approved, in combination with other anticancer agents (e.g., a platinum agent and etoposide or vinblastine, in a regimen such as VIP), as third-line chemotherapy for germ cell testicular cancer that has not responded to, or has relapsed after, appropriate first-line therapy.

Guideline-Supported / Off-Label Uses (Combination Therapy Only)

• Soft tissue sarcoma and osteosarcoma: used off-label as part of multi-agent chemotherapy regimens per oncology treatment guidelines.
• Ewing sarcoma and rhabdomyosarcoma (pediatric and adult): used off-label as part of combination protocols in specialized oncology centers.
• Relapsed/refractory lymphoma: used off-label as part of combination regimens (e.g., ICE, IVAC) usually as a bridge to stem cell transplant.
• Other solid tumors (e.g., cervical cancer, non-small cell lung cancer, ovarian cancer) in selected patients, always as part of combination chemotherapy and only when directed by a treating oncologist.

Holoxan is never used as a stand-alone, first-line treatment; it is always given as part of a physician-directed combination chemotherapy protocol along with mandatory supportive care (see Dosage and Administration).

Each vial contains Ifosfamide USP as a sterile, white, lyophilized (freeze-dried) powder for reconstitution and intravenous infusion, commonly available in strengths such as 1 g and 3 g per vial. It contains no other active pharmaceutical ingredient.

Holoxan is a synthetic alkylating agent belonging to the oxazaphosphorine class, chemically related to cyclophosphamide. It is supplied as a sterile powder that must be reconstituted before intravenous administration.

Because Holoxan is cytotoxic and carries serious dose-limiting toxicities (bladder toxicity, bone marrow suppression, and nervous system toxicity), it is administered only in a hospital or specialized oncology infusion setting by, or under the direct supervision of, a physician experienced in the use of cancer chemotherapeutic agents, together with mandatory supportive measures (mesna and hydration).

Holoxan belongs to the alkylating agent class of antineoplastic (anticancer) medicines, specifically the oxazaphosphorine subclass (nitrogen mustard analog), which also includes cyclophosphamide.

Mechanism of Action

Ifosfamide is an inactive prodrug that requires hepatic activation by the cytochrome P450 enzyme system (mainly CYP3A4 and CYP2B6) to form 4-hydroxyifosfamide, which is in equilibrium with its tautomer, aldoifosfamide. Aldoifosfamide breaks down non-enzymatically into the active alkylating species, ifosforamide mustard, plus the reactive byproducts acrolein (responsible for urotoxicity) and chloroacetaldehyde (implicated in central nervous system and kidney toxicity).

Ifosforamide mustard cross-links DNA strands (mainly at the N7 position of guanine), preventing DNA replication and transcription. This alkylation is not specific to any single phase of the cell cycle, leading to cell death, particularly in rapidly dividing malignant cells.

Pharmacokinetics

Ifosfamide is administered intravenously and undergoes extensive hepatic metabolism. It is eliminated mainly via the kidneys, with a substantial portion excreted as unchanged drug and metabolites in urine — one reason why adequate hydration and urinary monitoring are essential during treatment.

Holoxan is administered only by, or under the direct supervision of, a physician or oncology nurse experienced in cancer chemotherapy, in a hospital or specialized infusion center. It must never be self-administered.

• Reconstituted and further diluted Holoxan solution is given as a slow intravenous infusion over at least 30 minutes (longer infusions or continuous infusion protocols are also used).
• Mesna and adequate hydration must be given alongside every dose to reduce the risk of bladder toxicity (see Dosage and Administration).
• Extravasation should be avoided; the infusion site should be monitored during administration.
• Standard precautions for handling and disposal of hazardous/cytotoxic drugs should be followed by healthcare personnel.

Holoxan has clinically important interactions with medicines that affect the cytochrome P450 (CYP3A4/CYP2B6) enzymes responsible for its activation, and with other drugs that add to its toxicities.

• CYP450 enzyme inducers (e.g., phenytoin, phenobarbital, carbamazepine, rifampin): may increase the formation of toxic metabolites, raising the risk of central nervous system and kidney toxicity.
• CYP450 enzyme inhibitors (e.g., ketoconazole, itraconazole, aprepitant): may reduce hepatic activation of Holoxan, potentially decreasing its anticancer effectiveness.
• Other myelosuppressive or nephrotoxic drugs (e.g., other chemotherapy agents, aminoglycoside antibiotics, cisplatin): additive bone marrow suppression and/or kidney toxicity.
• Warfarin and other anticoagulants: chemotherapy including Holoxan may alter anticoagulant response; more frequent monitoring of coagulation status (INR) is advised.
• Live or live-attenuated vaccines: should generally be avoided during and shortly after Holoxan therapy because of the risk of disseminated infection in an immunosuppressed patient.

Patients should inform their oncologist of all prescription medicines, over-the-counter drugs, and herbal supplements before starting Holoxan.

Holoxan commonly causes side effects related to its cytotoxic mechanism. Patients are monitored closely by their oncology team throughout treatment.

Very Common

• Alopecia (hair loss) — occurs in the large majority of patients.
• Nausea and vomiting.
• Myelosuppression: leukopenia, thrombocytopenia, anemia (increases infection and bleeding risk).
• Hemorrhagic cystitis / hematuria (blood in urine) — reduced substantially, but not eliminated, by mesna.

Common / Serious

• Central nervous system toxicity: confusion, somnolence, dizziness, hallucinations, and rarely severe encephalopathy or coma.
• Nephrotoxicity, including renal tubular dysfunction.
• Fatigue, anorexia, mucositis (mouth sores).
• Infection due to immunosuppression.
• Elevated liver enzymes.

Patients should seek urgent medical attention for fever, signs of infection, severe confusion, difficulty urinating, visible blood in urine, or unusual bleeding/bruising.

Pregnancy: Holoxan can cause fetal harm and is associated with embryo-fetal toxicity based on its mechanism of action and animal/human data. It should be strictly avoided during pregnancy. If used during pregnancy, or if the patient becomes pregnant while receiving Holoxan, she should be informed of the potential risk to the fetus. Women of reproductive potential and men with partners of reproductive potential should use effective contraception during, and for a period after, treatment; a physician should be consulted regarding family planning.

Lactation: It is not known whether Holoxan is excreted in human breast milk, but because of the potential for serious adverse effects in a nursing infant, breastfeeding should be avoided during treatment with Holoxan and for an appropriate interval afterward, as advised by the treating physician.

Boxed Warnings

• Urotoxicity (hemorrhagic cystitis): Holoxan can cause severe, sometimes fatal, bladder toxicity. Concurrent mesna administration and vigorous hydration are required with every dose to reduce this risk; urine should be checked for blood before each dose.
• Myelosuppression: Holoxan causes dose-limiting suppression of bone marrow function, which can lead to serious or fatal infections and bleeding. Blood counts must be monitored regularly.
• Central nervous system toxicity: Encephalopathy, confusion, and somnolence can occur and may be severe, rarely progressing to coma; symptoms usually resolve after stopping the drug, but caution is required and neurological status should be monitored.
• Holoxan must be administered only under the supervision of a physician experienced in the use of cancer chemotherapeutic agents.

Other Precautions

• Use with caution in patients with an active urinary tract infection because of the added risk of urotoxicity; the infection should generally be treated before starting therapy.
• Renal and hepatic function should be assessed before and monitored during treatment.
• Holoxan is immunosuppressive; patients should avoid close contact with people who have active infections and should not receive live vaccines without medical advice.
• Holoxan may impair fertility in both men and women.
• Patients should be advised of the small increased long-term risk of secondary malignancy associated with alkylating agent chemotherapy.

Overdose of Holoxan can cause severe or life-threatening bone marrow suppression, hemorrhagic cystitis, and central nervous system toxicity. There is no specific antidote. Any suspected overdose is a medical emergency — the patient's oncology team or emergency medical services should be contacted immediately for supportive care, which may include intensive monitoring, blood product support, and other measures as directed by the treating physicians. Do not attempt to manage a suspected overdose at home.

Store vials at controlled room temperature, generally 20°C–25°C (68°F–77°F), protected from light and moisture, and keep out of reach of children. This medicine is stored, reconstituted, and handled by qualified hospital/pharmacy personnel; reconstituted or diluted solutions have limited stability and are used according to the pharmacy's protocol, typically within 24 hours if refrigerated.

Pediatric Use

Holoxan is used off-label in pediatric oncology (e.g., in sarcoma and certain solid tumor protocols) under the direction of a pediatric oncologist; formal safety and efficacy have not been established by the manufacturer's approved labeling, so its use in children relies on published cooperative-group protocols and specialist judgment.

Elderly

Older adults may be more susceptible to myelosuppression, kidney impairment, and central nervous system toxicity; dose selection and monitoring should be individualized, generally starting with careful assessment of renal function.

Renal Impairment

Reduced clearance increases toxicity risk; dose adjustment, enhanced monitoring, or avoidance is needed depending on severity (see Dosage and Administration and Contraindications).

Hepatic Impairment

May alter activation and toxicity of Holoxan; use with caution and close monitoring, as there are no well-established formal dosing guidelines.

Duration of Holoxan treatment depends on the specific chemotherapy protocol, cancer type, and patient response, and is determined by the treating oncologist. Typical regimens involve multi-day cycles (e.g., 5 consecutive days of infusion) repeated every 3 weeks for a defined number of cycles, with ongoing reassessment of response and toxicity between cycles.

Holoxan for injection is a lyophilized (freeze-dried) powder that must be reconstituted before use. It is typically reconstituted with sterile water for injection to a concentration of approximately 50 mg/mL, then further diluted in a compatible intravenous fluid (such as 5% dextrose, 0.9% sodium chloride, or lactated Ringer's solution) before infusion. Reconstitution and dilution must be performed by trained pharmacy or nursing personnel using proper aseptic and cytotoxic-drug handling technique, following the product's specific instructions for the concentration and stability of the prepared solution.

Ifosfamide is classified as an antineoplastic alkylating agent, in the oxazaphosphorine (nitrogen mustard analog) subclass.

Ifosfamide is a prodrug activated in the liver (mainly by CYP3A4/CYP2B6) to form the active alkylating metabolite ifosforamide mustard, which cross-links DNA strands and prevents cell replication, leading to death of rapidly dividing cancer cells. Byproducts of activation (acrolein and chloroacetaldehyde) are responsible for the drug's characteristic bladder and nervous system toxicities.

D

Holoxan is not FDA-approved for a specific pediatric indication, and formal safety and efficacy in children have not been established in the approved product labeling. Nonetheless, it is used off-label in pediatric oncology as part of published multi-agent protocols for cancers such as Ewing sarcoma, rhabdomyosarcoma, and other solid tumors, under the direct supervision of a pediatric oncologist experienced with these regimens, with the same mandatory mesna, hydration, and monitoring precautions used in adults, adjusted for body surface area.